The development of selective PDE inhibitors, as well as the selection of the appropriate subgroup of participants in future relative clinical trials may aid in us in obtaining a better understanding of the therapeutic potential of ibudilast in neurodegenerative diseases. This evidence concerns the gene ALDH7A1 and neurodegenerative disease.